Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

被引:26
|
作者
Quenel-Tueux, Nathalie [1 ]
Debled, Marc [1 ]
Rudewicz, Justine [1 ,2 ,3 ,4 ,5 ]
MacGrogan, Gaetan [1 ,2 ,3 ]
Pulido, Marina [6 ,7 ]
Mauriac, Louis [1 ]
Dalenc, Florence [8 ]
Bachelot, Thomas [9 ]
Lortal, Barbara [1 ]
Breton-Callu, Christelle [1 ]
Madranges, Nicolas [1 ]
de lara, Christine Tunon [1 ]
Fournier, Marion [1 ]
Bonnefoi, Herve [1 ,2 ,3 ]
Soueidan, Hayssam [4 ]
Nikolski, Macha [3 ,4 ,5 ]
Gros, Audrey [1 ,2 ,3 ]
Daly, Catherine [10 ]
Wood, Henry [10 ]
Rabbitts, Pamela [10 ]
Iggo, Richard [1 ,2 ,3 ]
机构
[1] Inst Bergonie, Ctr Comprehens Canc, F-33000 Bordeaux, France
[2] INSERM, U916, F-33000 Bordeaux, France
[3] Univ Bordeaux, F-33608 Pessac, France
[4] Univ Bordeaux, Bordeaux Bioinformat Ctr, F-33076 Bordeaux, France
[5] CNRS, UMR5800, Bordeaux Comp Sci Lab, F-33405 Talence, France
[6] INSERM, Clin Invest Ctr, CIC1401, Epidemiol Unit, F-33076 Bordeaux, France
[7] Inst Bergonie, Clin & Epidemiol Res Unit, F-33076 Bordeaux, France
[8] Inst Claudius Regaud, IUCT Oncopole Toulouse, F-31059 Toulouse, France
[9] CLCC Lyon, F-69008 Lyon, France
[10] Univ Leeds, Leeds Inst Canc & Pathol, Leeds LS9 7TF, W Yorkshire, England
关键词
anastrozole; endocrine treatment; fulvestrant; hormone-receptor-positive cancer; large operable or locally advanced breast cancer; neo-adjuvant; NEOADJUVANT ENDOCRINE THERAPY; KI-67 LABELING INDEX; DOUBLE-BLIND; TAMOXIFEN; WOMEN; LETROZOLE; CHEMOTHERAPY; KI67;
D O I
10.1038/bjc.2015.247
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to assess the efficacy of neoadjuvant anastrozole and fulvestrant treatment of large operable or locally advanced hormone-receptor-positive breast cancer not eligible for initial breast-conserving surgery, and to identify genomic changes occurring after treatment. Methods: One hundred and twenty post-menopausal patients were randomised to receive 1mg anastrozole (61 patients) or 500mg fulvestrant (59 patients) for 6 months. Genomic DNA copy number profiles were generated for a subgroup of 20 patients before and after treatment. Results: A total of 108 patients were evaluable for efficacy and 118 for toxicity. The objective response rate determined by clinical palpation was 58.9% (95% CI = 45.0-71.9) in the anastrozole arm and 53.8% (95% CI = 39.5-67.8) in the fulvestrant arm. The breast-conserving surgery rate was 58.9% (95% CI = 45.0-71.9) in the anastrozole arm and 50.0% (95% CI = 35.8-64.2) in the fulvestrant arm. Pathological responses >50% occurred in 24 patients (42.9%) in the anastrozole arm and 13 (25.0%) in the fulvestrant arm. The Ki-67 score fell after treatment but there was no significant difference between the reduction in the two arms (anastrozole 16.7% (95% CI = 13.3-21.0) before, 3.2% (95% CI = 1.9-5.5) after, n = 43; fulvestrant 17.1% (95% CI = 13.1-22.5) before, 3.2% (95% CI = 1.8-5.7) after, n = 38) or between the reduction in Ki-67 in clinical responders and non-responders. Genomic analysis appeared to show a reduction of clonal diversity following treatment with selection of some clones with simpler copy number profiles. Conclusions: Both anastrozole and fulvestrant were effective and well-tolerated, enabling breast-conserving surgery in over 50% of patients. Clonal changes consistent with clonal selection by the treatment were seen in a subgroup of patients.
引用
收藏
页码:585 / 594
页数:10
相关论文
共 50 条
  • [21] Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study
    Mark J. Clemons
    Brandy Cochrane
    Gregory R. Pond
    Nadia Califaretti
    Stephen K. L. Chia
    Rebecca Alexandra Dent
    Xinni Song
    Andre Robidoux
    Sameer Parpia
    David Warr
    Daniel Rayson
    Kathleen I. Pritchard
    Mark N. Levine
    Breast Cancer Research and Treatment, 2014, 146 : 153 - 162
  • [22] ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany
    Maass, Nicolai
    Ostermann, Helmut
    Possinger, Kurt
    Klein, Peter
    Tesch, Hans
    Muehlenhoff, Lars
    Bauerschlag, Dirk O.
    BREAST CARE, 2019, 14 (06) : 401 - 408
  • [23] Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
    Bachelot, Thomas
    McCool, Rachael
    Duffy, Steven
    Glanville, Julie
    Varley, Danielle
    Fleetwood, Kelly
    Zhang, Jie
    Jerusalem, Guy
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (01) : 125 - 133
  • [24] Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
    Robertson, John F. R.
    Bondarenko, Igor M.
    Trishkina, Ekaterina
    Dvorkin, Mikhail
    Panasci, Lawrence
    Manikhas, Alexey
    Shparyk, Yaroslav
    Cardona-Huerta, Servando
    Cheung, Kwok-Leung
    Philco-Salas, Manuel Jesus
    Ruiz-Borrego, Manuel
    Shao, Zhimin
    Noguchi, Shinzaburo
    Rowbottom, Jacqui
    Stuart, Mary
    Grinsted, Lynda M.
    Fazal, Mehdi
    Ellis, Matthew J.
    LANCET, 2016, 388 (10063): : 2997 - 3005
  • [25] A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer
    Tolaney, Sara M.
    Jeong, Joon
    Guo, Hao
    Brock, Jane
    Morganstern, Daniel
    Come, Steven E.
    Golshan, Mehra
    Bellon, Jennifer
    Winer, Eric P.
    Krop, Ian E.
    CANCER MEDICINE, 2014, 3 (02): : 293 - 299
  • [26] Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Schwartzberg, Lee S.
    Wang, Grace
    Somer, Bradley G.
    Blakely, L. Johnetta
    Wheeler, Benton M.
    Walker, Mark S.
    Stepanski, Edward J.
    Houts, Arthur C.
    CLINICAL BREAST CANCER, 2014, 14 (01) : 13 - 19
  • [27] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
    Bergh, Jonas
    Jonsson, Per-Ebbe
    Lidbrink, Elisabet Kerstin
    Trudeau, Maureen
    Eiermann, Wolfgang
    Brattstrom, Daniel
    Lindemann, Justin P. O.
    Wiklund, Fredrik
    Henriksson, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1919 - 1925
  • [28] Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
    Ciruelos, E.
    Vidal, M.
    Martinez de Duenas, E.
    Martinez-Janez, N.
    Fernandez, Y.
    Garcia-Saenz, J. A.
    Murillo, L.
    Carabantes, F.
    Beliera, A.
    Fonseca, R.
    Gavila, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06): : 753 - 760
  • [29] Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)
    Noguchi, Shinzaburo
    Ellis, Matthew J.
    Robertson, John F. R.
    Thirlwell, Jackie
    Fazal, Mehdi
    Shao, Zhimin
    BREAST CANCER, 2018, 25 (03) : 356 - 364
  • [30] A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
    Hiroji Iwata
    Norikazu Masuda
    Shinji Ohno
    Yoshiaki Rai
    Yasuyuki Sato
    Shozo Ohsumi
    Satoshi Hashigaki
    Yoshinori Nishizawa
    Masahiro Hiraoka
    Tadaoki Morimoto
    Hironobu Sasano
    Toshiaki Saeki
    Shinzaburo Noguchi
    Breast Cancer Research and Treatment, 2013, 139 : 441 - 451